Sector News

Bayer cuts loose diabetes care division for 1.02bn euros

June 10, 2015
Life sciences
Bayer is shedding its diabetes care division via a deal with long-term partner Panasonic Healthcare Holdings worth 1.02 billion euros.
 
The sale includes blood glucose monitoring systems, including the popular Contour portfolio of testers and strips, as well as lancing devices for patients with diabetes, which helped the unit bring in sales of 909 million euros last year.
 
The move seems a good fit for Panasonic. “For more than 20 years, our companies have shared complementary goals. We anticipate that this partnership will take our two great businesses to new heights,” said Kenji Yamane, President of Panasonic Healthcare Holdings, which is owned by investment group KKR (80%) and Panasonic Corp (20%). 
 
For Bayer, the transaction comes under its current strategy of honing its focus on life-sciences, as per which it also plans to de-merge and float on the stock market its MaterialScience unit by mid-2016.
 
The deal with Panasonic, which remains subject to customary conditions, including relevant antitrust clearance, is expected to close in the first quarter of next year.
 
By Selina McKee
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach